Higher Female TSH Associated With Lower Mannan-Binding Lectin
|
By LabMedica International staff writers Posted on 15 Jan 2020 |

Image: Synergy H1 Hybrid Multi-Mode Reader is a configurable microplate reader (Photo courtesy of BioTek)
Mannan-binding lectin (MBL) is a main component of the lectin pathway of the complement system. Lower MBL levels are associated with, among other conditions, hypothyroidism and adverse pregnancy outcomes.
In turn, adverse pregnancy outcomes and infertility may result from hypothyroidism, even in patients with high normal thyroid-stimulating hormone (TSH). An increased MBL blood level was found in hyperthyroid patients while decreased MBL levels were found in hypothyroid patients.
Endocrinologists at the Medical University of Lodz (Lodz, Poland) tested patients who were divided into two groups of 70 patients with low normal TSH (< 2.5 mIU/L) (Controls), and 25 patients (26.3% of the whole sample examined) with high normal TSH (≥2.5 mIU/L), which were well matched at baseline in terms of age and body mass index (BMI). Nineteen patients were previously diagnosed to be hypothyroid and therefore they were treated with L-thyroxine (25–150 μg daily).
The team measured in serum hormones (TSH, FT4, FT3), thyroid antibodies (i.e. thyroid peroxidase antibodies (TPOAb), thyroglobulin antibodies (TgAb) and thyrotropin receptor antibodies (TSHRAb)), among other laboratory parameters (such as total cholesterol, high-density lipoprotein cholesterol (HDLC), low-density lipoprotein cholesterol (LDLC), HDLC/cholesterol ratio, triglycerides (TGs), glucose, C-reactive protein (CRP), iron, and lipid peroxidation. Serum concentration of MBL was measured by an enzyme-linked immunosorbent assay (ELISA) using a commercial human MBL ELISA kit (RayBiotech, Inc, Peachtree Corners, GA, USA), with a detection threshold of 0.03 ng/mL. The readings were performed on a Synergy H1 microplate reader (BioTek, Winooski, VT, USA) with a wavelength of 450 nm.
The investigators found that serum MBL level was lower in women with TSH ≥ 2.5 mIU/L than with TSH < 2.5 mIU/L. This association was confirmed by univariate regression analysis. MBL level was significantly lower in patients with abnormally low HDLC/cholesterol ratio and a positive correlation was found between MBL level and HDL/cholesterol ratio. MBL level was not statistically associated with L-thyroxine treatment when evaluated by the univariate logistic regression analysis. MBL level did not correlate with either TPOAb or TgAb.
The authors concluded that in women of reproductive age with normal thyroid tests, lower MBL is associated with high normal TSH and with less favorable lipid profile. Therefore, treatment with L-thyroxine should be considered in women of reproductive age with TSH ≥ 2.5 mIU/l. The study was published on January 3, 2020 in the journal BMC Endocrine Disorders.
Related Links:
Medical University of Lodz
RayBiotech Inc
BioTek
In turn, adverse pregnancy outcomes and infertility may result from hypothyroidism, even in patients with high normal thyroid-stimulating hormone (TSH). An increased MBL blood level was found in hyperthyroid patients while decreased MBL levels were found in hypothyroid patients.
Endocrinologists at the Medical University of Lodz (Lodz, Poland) tested patients who were divided into two groups of 70 patients with low normal TSH (< 2.5 mIU/L) (Controls), and 25 patients (26.3% of the whole sample examined) with high normal TSH (≥2.5 mIU/L), which were well matched at baseline in terms of age and body mass index (BMI). Nineteen patients were previously diagnosed to be hypothyroid and therefore they were treated with L-thyroxine (25–150 μg daily).
The team measured in serum hormones (TSH, FT4, FT3), thyroid antibodies (i.e. thyroid peroxidase antibodies (TPOAb), thyroglobulin antibodies (TgAb) and thyrotropin receptor antibodies (TSHRAb)), among other laboratory parameters (such as total cholesterol, high-density lipoprotein cholesterol (HDLC), low-density lipoprotein cholesterol (LDLC), HDLC/cholesterol ratio, triglycerides (TGs), glucose, C-reactive protein (CRP), iron, and lipid peroxidation. Serum concentration of MBL was measured by an enzyme-linked immunosorbent assay (ELISA) using a commercial human MBL ELISA kit (RayBiotech, Inc, Peachtree Corners, GA, USA), with a detection threshold of 0.03 ng/mL. The readings were performed on a Synergy H1 microplate reader (BioTek, Winooski, VT, USA) with a wavelength of 450 nm.
The investigators found that serum MBL level was lower in women with TSH ≥ 2.5 mIU/L than with TSH < 2.5 mIU/L. This association was confirmed by univariate regression analysis. MBL level was significantly lower in patients with abnormally low HDLC/cholesterol ratio and a positive correlation was found between MBL level and HDL/cholesterol ratio. MBL level was not statistically associated with L-thyroxine treatment when evaluated by the univariate logistic regression analysis. MBL level did not correlate with either TPOAb or TgAb.
The authors concluded that in women of reproductive age with normal thyroid tests, lower MBL is associated with high normal TSH and with less favorable lipid profile. Therefore, treatment with L-thyroxine should be considered in women of reproductive age with TSH ≥ 2.5 mIU/l. The study was published on January 3, 2020 in the journal BMC Endocrine Disorders.
Related Links:
Medical University of Lodz
RayBiotech Inc
BioTek
Latest Immunology News
- New Test Distinguishes Vaccine-Induced False Positives from Active HIV Infection
- Gene Signature Test Predicts Response to Key Breast Cancer Treatment
- Chip Captures Cancer Cells from Blood to Help Select Right Breast Cancer Treatment
- Blood-Based Liquid Biopsy Model Analyzes Immunotherapy Effectiveness
- Signature Genes Predict T-Cell Expansion in Cancer Immunotherapy
- Molecular Microscope Diagnostic System Assesses Lung Transplant Rejection
- Blood Test Tracks Treatment Resistance in High-Grade Serous Ovarian Cancer
- Luminescent Probe Measures Immune Cell Activity in Real Time
- Blood-Based Immune Cell Signatures Could Guide Treatment Decisions for Critically Ill Patients
- Novel Tool Predicts Most Effective Multiple Sclerosis Medication for Patients
- Companion Diagnostic Test for CRC Patients Identifies Eligible Treatment Population
- Novel Tool Uses Deep Learning for Precision Cancer Therapy
- Companion Diagnostic Test Identifies HER2-Ultralow Breast Cancer and Biliary Tract Cancer Patients
- Novel Multiplex Assay Supports Diagnosis of Autoimmune Vasculitis
- Blood Test Predicts Immunotherapy Efficacy in Triple-Negative Breast Cancer
- Simple Genetic Testing Could Predict Treatment Success in Multiple Sclerosis Patients
Channels
Molecular Diagnostics
view channel
Simple Urine Test to Revolutionize Bladder Cancer Diagnosis and Treatment
Bladder cancer is one of the most common and deadly urological cancers and is marked by a high rate of recurrence. Diagnosis and follow-up still rely heavily on invasive cystoscopy or urine cytology, which... Read more
Blood Test to Enable Earlier and Simpler Detection of Liver Fibrosis
Persistent liver damage caused by alcohol misuse or viral infections can trigger liver fibrosis, a condition in which healthy tissue is gradually replaced by collagen fibers. Even after successful treatment... Read moreHematology
view channel
Platelet Activity Blood Test in Middle Age Could Identify Early Alzheimer’s Risk
Early detection of Alzheimer’s disease remains one of the biggest unmet needs in neurology, particularly because the biological changes underlying the disorder begin decades before memory symptoms appear.... Read more
Microvesicles Measurement Could Detect Vascular Injury in Sickle Cell Disease Patients
Assessing disease severity in sickle cell disease (SCD) remains challenging, especially when trying to predict hemolysis, vascular injury, and risk of complications such as vaso-occlusive crises.... Read more
ADLM’s New Coagulation Testing Guidance to Improve Care for Patients on Blood Thinners
Direct oral anticoagulants (DOACs) are one of the most common types of blood thinners. Patients take them to prevent a host of complications that could arise from blood clotting, including stroke, deep... Read moreImmunology
view channel
New Test Distinguishes Vaccine-Induced False Positives from Active HIV Infection
Since HIV was identified in 1983, more than 91 million people have contracted the virus, and over 44 million have died from related causes. Today, nearly 40 million individuals worldwide live with HIV-1,... Read more
Gene Signature Test Predicts Response to Key Breast Cancer Treatment
DK4/6 inhibitors paired with hormone therapy have become a cornerstone treatment for advanced HR+/HER2– breast cancer, slowing tumor growth by blocking key proteins that drive cell division.... Read more
Chip Captures Cancer Cells from Blood to Help Select Right Breast Cancer Treatment
Ductal carcinoma in situ (DCIS) accounts for about a quarter of all breast cancer cases and generally carries a good prognosis. This non-invasive form of the disease may or may not become life-threatening.... Read moreMicrobiology
view channel
Rapid Diagnostic Test Matches Gold Standard for Sepsis Detection
Sepsis kills 11 million people worldwide every year and generates massive healthcare costs. In the USA and Europe alone, sepsis accounts for USD 100 billion in annual hospitalization expenses.... Read moreRapid POC Tuberculosis Test Provides Results Within 15 Minutes
Tuberculosis remains one of the world’s deadliest infectious diseases, and reducing new cases depends on identifying individuals with latent infection before it progresses. Current diagnostic tools often... Read more
Rapid Assay Identifies Bloodstream Infection Pathogens Directly from Patient Samples
Bloodstream infections in sepsis progress quickly and demand rapid, precise diagnosis. Current blood-culture methods often take one to five days to identify the pathogen, leaving clinicians to treat blindly... Read morePathology
view channel
Tunable Cell-Sorting Device Holds Potential for Multiple Biomedical Applications
Isolating rare cancer cells from blood is essential for diagnosing metastasis and guiding treatment decisions, but remains technically challenging. Many existing techniques struggle to balance accuracy,... Read moreAI Tool Outperforms Doctors in Spotting Blood Cell Abnormalities
Diagnosing blood disorders depends on recognizing subtle abnormalities in cell size, shape, and structure, yet this process is slow, subjective, and requires years of expert training. Even specialists... Read moreTechnology
view channel
Artificial Intelligence Model Could Accelerate Rare Disease Diagnosis
Identifying which genetic variants actually cause disease remains one of the biggest challenges in genomic medicine. Each person carries tens of thousands of DNA changes, yet only a few meaningfully alter... Read more
AI Saliva Sensor Enables Early Detection of Head and Neck Cancer
Early detection of head and neck cancer remains difficult because the disease produces few or no symptoms in its earliest stages, and lesions often lie deep within the head or neck, where biopsy or endoscopy... Read moreIndustry
view channel
Abbott Acquires Cancer-Screening Company Exact Sciences
Abbott (Abbott Park, IL, USA) has entered into a definitive agreement to acquire Exact Sciences (Madison, WI, USA), enabling it to enter and lead in fast-growing cancer diagnostics segments.... Read more








